Novo Nordisk has purchased the Berkeley Lights, Inc. Beacon Optofluidic platform to accelerate workflows in cell line development and to use the platform for future protein and antibody discovery. The Beacon platform reduces the extensive resources typically required to generate a cell line for commercial production by allowing for parallel screening, maintenance, and analysis of thousands of…